These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 708161)

  • 41. [The metabolic clearance rate of antipyrine: a good index for the assessment of the hepatic drug-oxidizing function in cirrhotic patients (author's transl)].
    Miguet JP; Allemand H; Joanne C; Dhumeaux D
    Nouv Presse Med; 1978 Dec; 7(46):4209-11. PubMed ID: 745958
    [No Abstract]   [Full Text] [Related]  

  • 42. Lack of stimulation of antipyrine and phenytoin metabolism by lithium carbonate in man.
    Perrild H; Hansen JM; Skovsted L; Simonsen K; Hegedüs L; Christensen LK
    Acta Pharmacol Toxicol (Copenh); 1983 Apr; 52(4):315-7. PubMed ID: 6408891
    [No Abstract]   [Full Text] [Related]  

  • 43. Hepatic microsomal oxidative N-demethylation in rats with renal failure [proceedings].
    Hogan EM; Nicholls PJ; Yoosuf A
    Br J Pharmacol; 1979 May; 66(1):74P-75P. PubMed ID: 454960
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of pressure on oxidative metabolism of drugs by mouse hepatic microsomes.
    Marriage HJ; Paton WD; Harvey DJ
    Undersea Biomed Res; 1986 Sep; 13(3):369-81. PubMed ID: 3022437
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phenylbutazone protein binding in normal subjects and hypoproteinemic patients.
    Kshirsagar NA; Pahujani SM; Paul T; Sheth UK
    Indian J Med Res; 1979 Dec; 70():1006-9. PubMed ID: 540998
    [No Abstract]   [Full Text] [Related]  

  • 46. Potential molecular targets mediating chemical teratogenesis: in vitro peroxidase-catalyzed phenytoin metabolism and oxidative damage to proteins and lipids in murine maternal hepatic microsomes and embryonic 9000g supernatant.
    Liu L; Wells PG
    Toxicol Appl Pharmacol; 1995 Sep; 134(1):71-80. PubMed ID: 7676459
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Biotransformation of ketophenylbutazone in vitro].
    Queisnerová M; Siblíková O; Veverková M; Macek K; Nĕmecek O
    Cesk Farm; 1967 Jun; 16(5):219-22. PubMed ID: 6077826
    [No Abstract]   [Full Text] [Related]  

  • 48. [Hepatic metabolism of antipyrine in patients with acute pancreatitis].
    Lukaszyk A
    Przegl Lek; 1987; 44(2):273-6. PubMed ID: 3615930
    [No Abstract]   [Full Text] [Related]  

  • 49. Drug metabolism in normal children, lead-poisoned children, and normal adults.
    Alvares AP; Kapelner S; Sassa S; Kappas A
    Clin Pharmacol Ther; 1975 Feb; 17(2):179-83. PubMed ID: 804369
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [In vivo activity of drug-metabolizing enzymes in various pathological conditions].
    Krakovskiĭ ME; Ashirmetov AKh
    Vopr Med Khim; 1985; 31(1):76-9. PubMed ID: 3984279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antipyrine metabolism and bronchogenic carcinoma.
    Ambre J; Graeff D; Bures F; Haupt D; Deason K
    J Med; 1977; 8(1):57-70. PubMed ID: 267157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The metabolism of phenylbutazone in the rat.
    Bakke OM; Draffan GH; Davies DS
    Xenobiotica; 1974 Apr; 4(4):237-54. PubMed ID: 4603132
    [No Abstract]   [Full Text] [Related]  

  • 53. Antipyrine as a model drug substance to assess oxidative metabolism.
    Konig PK; Cantilena L
    Arch Intern Med; 1994 Mar; 154(5):590. PubMed ID: 8122953
    [No Abstract]   [Full Text] [Related]  

  • 54. Metabolism of 14C-antipyrine in suspensions of isolated rat liver cells.
    Aarbakke J; Bessesen A; Morland J
    Acta Pharmacol Toxicol (Copenh); 1977 Sep; 41(3):225-34. PubMed ID: 578651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Hydroxylation of phenylbutazone and imipramine by rabbit liver microsomes].
    LEYBOLD K; STAUDINGER H
    Z Gesamte Exp Med; 1962; 136():78-85. PubMed ID: 14464938
    [No Abstract]   [Full Text] [Related]  

  • 56. The metabolism of antipyrine in patients with chronic renal failure.
    Lichter M; Black M; Arias IM
    J Pharmacol Exp Ther; 1973 Dec; 187(3):612-9. PubMed ID: 4588969
    [No Abstract]   [Full Text] [Related]  

  • 57. A new polymorphism of hepatic drug oxidation in man: family studies on rates of formation of antipyrine metabolites.
    Vessell ES; Penno MB
    Biochem Soc Trans; 1984 Feb; 12(1):74-8. PubMed ID: 6705993
    [No Abstract]   [Full Text] [Related]  

  • 58. Individual differences in the disposition of drugs metabolised in the body.
    Alvan G
    Clin Pharmacokinet; 1978; 3(2):155-75. PubMed ID: 346288
    [No Abstract]   [Full Text] [Related]  

  • 59. Phenytoin binding to partially purified albumin in renal disease.
    Kinniburgh DW; Boyd ND
    Clin Pharmacol Ther; 1981 Feb; 29(2):203-10. PubMed ID: 7460484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro and in vivo studies of the metabolism of phenylbutazone in the alloxan rat and rabbit.
    Dajani RM; Saheb SE
    J Pharm Pharmacol; 1971 Dec; 23():220S-221S. PubMed ID: 4401469
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.